BioSpace News Archive

The collaboration will exploit Ymir’s proprietary urinary extracellular vesicle technology and the expertise of the Knight Cancer Institute supported OHSU Proteomics Shared Resource.

The cash will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene.

The dividend is payable on January 2, 2018, to stockholders of record as of December 1, 2017. The indicated annual dividend rate is $0.64 per share.

Riverain’s ClearRead CT install base has expanded in the U.S. as leading institutions see the value in its efficient and effective detection of lung nodules across all chest CTs, including lung cancer screening exams.

Net sales in the third quarter of 2017 were $1,354,000, compared to $1,417,000 in the third quarter 2016, a decrease of 4.4%.

Medicare beneficiaries in 23 additional states have been granted reimbursed access to the Transoral Incisionless Fundoplication (TIF) 2.0 procedure following positive coverage decisions by Medicare Administrative Contractors (MACs) Noridian Health Care Solutions (Noridian) and National Government Services, Inc. (NGS).

The CHMP positive opinion for ADCETRIS will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union (EU), Norway, Liechtenstein and Iceland.

The study demonstrated no adverse clinical findings after repeated intravenous administration of the maximum achievable dose of 3DNA nanocarrier.

Debio 1347 is an orally available small molecule selectively targeting FGFR 1, 2, 3 signaling pathways and is currently tested in a phase I study in patients with FGFR genomically activated advanced solid tumors.

The claims cover small molecule candidates and the family around these candidates and their human use, adding to the patent coverage in the US and elsewhere.